Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW Noble, C Albera, WZ Bradford, U Costabel… - The Lancet, 2011 - thelancet.com
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
[引用][C] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW NOBLE, C ALBERA, D VALEYRE… - Lancet (British …, 2011 - pascal-francis.inist.fr
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
CNRS Inist Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW Noble, C Albera, WZ Bradford, U Costabel… - The Lancet, 2011 - infona.pl
Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of
lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm …
lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW Noble, C Albera, WZ Bradford, U Costabel… - Lancet, 2011 - boris.unibe.ch
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
P Noble, C Albera, W Bradford, U Costabel… - THE LANCET, 2011 - art.torvergata.it
BACKGROUND: Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
PW Noble, C Albera, WZ Bradford… - Lancet (London …, 2011 - europepmc.org
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
[引用][C] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
P Noble, C Albera, W Bradford, U Costabel… - THE LANCET, 2011 - arts.units.it
[引用][C] Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
P Noble, C Albera, W Bradford, U Costabel… - THE …, 2011 - research.unipd.it
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
PW Noble, C Albera, WZ Bradford, U Costabel… - THE …, 2011 - usiena-air.unisi.it
Background Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
inevitable loss of lung function. The CAPACITY programme (studies 004 and 006) was …
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
PW Noble, C Albera, WZ Bradford… - The Lancet (British …, 2011 - scholarship.miami.edu
Idiopathic pulmonary fibrosis is a progressive and fatal lung disease with inevitable loss of
lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm …
lung function. The CAPACITY programme (studies 004 and 006) was designed to confirm …